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GENERAL PRINCIPLES OF HEMOFILTRATION 
Renal failure is a recognized feature of the acutely ill, 
intensive care patient, often in association with multi- 
organ failure. Henlofiltration is now routinely used for 
treating acute renal failure in the intensive care unit 
(ICU). Unlike hemodialysis and peritoneal dialysis, 
both of which rely upon diffusion of molecules 
across a concentration gradient, hemofiltration utilizes 
convective solute transport (known as solvent drag) 
whereby molecules are swept along by a moving stream 
of solvent [l]. This is analogous to the filtration that 
occurs naturally through the glomerulus. A special 
filter is used to remove plasma water and unbound 
particles weighing between 500 and 10 000 Da. The 
nitrogenous substances traditionally associated with 
uremia are removed, although urea itself i s  not 
efficiently filtered. The process results in the produc- 
tion of a large volume of filtrate containing an excess 
of waste particles. The deficit of water and electrolytes 
are made good by infusing fluid back into the patient's 
blood, usually after it has passed through the filter 
(Figure 1). 
Continuous hemofiltration (CH) was first used 
to treat a patient with renal failure in 1977 [2]. The 
shortage of technical equipment and specialist staff 
required to provide hemodialysis, combined with 
excellent tolerance even in hemodynanlically compro- 
mised patients, have been the main reasons for its 
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development. Furthermore, fluid balance can be 
accurately controlled and regulated, allowing other 
support measures such as total parenteral nutrition to 
be used [3]. Unlike CH, peritoneal dialysis is less suited 
to the ICU as there is a delay before beneficial effects 
are seen and it cannot be used in the presence of intra- 
abdominal wounds, infection, ileus, or with a vascular 
prosthesis [4]. 
Although the underlying principle remains the 
same, several modifications of hernofiltration are in 
use [5]. The two commonest variations are continuous 
venovenous hernofiltration (CVVH) and continuous 
arteriovenous hemofiltration (CAVH). CAVH, which 
requires arterial access, is circulation driven, resulting in 
lower flow rates and filtrate volumes than CVHH. For 
it to be effective, a mean arterial pressure of 60 mmHg 
is required, making it less useful in the septic, hypo- 
tensive patient. CAVH has now been supplanted 
by CVVH, which is pump driven, achieving both 
higher flow rates and filtrate volumes, resulting in 
better clearance of waste products. C H  can also be 
supplemented by hemodialysis, particularly in the 
presence of a hypercatabolic state, to give continuous 
or intermittent hemodiafiltration [5-71. CVVH is 
performed via a dual lumen catheter inserted centrally, 
preferably into the jugular or subclavian vein, but 
femoral catheterization may be necessary when access 
at other sites is compromised [7]. 
Kierdorf has reviewed the advantages and dis- 
advantages of C H  versus intermittent dialysis treatment 
and the problems that accompany hemodialysis in the 
ICU patient [XI. CH decreases APACHE I1 scores, 
significantly increases arterial blood pressure, avoids 
major fluctuations in electrolyte imbalances (which 
may improve cerebral function), and increases the 
survival rate for patients with multiple organ failure. 
These benefits are partly offset by the requirement 
for continuous anticoagulation, hyperlactatemia and 
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reduced efficiency in the control of azoteniia per unit 
tinie [S]. Indications for CH include an increasing 
variety of other conditions (Table 1) [9-111. Although 
there are no absolute contraindications to hemo- 
filtration, extra care is needed for patients at  increased 
risk of hemorrhage (e.g. in severe thrombocyto- 
penia), when the anticoagulation required may be 
problematic [9]. 
PREVENTION AND DIAGNOSIS OF 
HEMOFILTRATION-RELATED INFECTION 
As the procedure involves cannulation of a large 
vein, and with CAVH an artery, insertion should be 
regarded as a sterile procedure and subject to the same 
precautions as central venous catheters. This has been 
reviewed recently and recommendations emphasize 
that insertion should be considered a minor operation, 
but because of the condition of patients requiring C H  
and the need for other organ support (e.g. ventilation), 
it is rarely possible to perform the procedure in 
an operating theater [12]. As with central venous 
catheters, it is difficult to justify the routine use of 
prophylactic antibiotics to reduce the risk of infection. 
Handling of the cannulae should be kept to a mini- 
mum, apart from during use and flushing with heparin. 
It is advisable not to use the catheter for obtaining 
routine blood samples unless there is limited vascular 
access or infection at  that site is suspected. 
Unfortunately, there are no generally agreed 
clinical or microbiological definitions for diagnosing 
heniofiltration-related infections. Furthermore, infec- 
tive coniplications vary from center to center according 
to the techniques used for catheter insertion, culture 
protocols, type of patient and duration of treatment. 
Attempts to define hemofiltration-related infection 
should be based on guidelines similar to those of 
catheter-related infection [13-151. This would allow a 
more accurate assessment of infection risk among 
different patient groups. Definitions used to diagnose 
Table 1 Indications for hemofiltration 
Acute renal failure 
Fluid and electrolyte imbalancc 
Myoglobinuric acute renal failure 
Total parenteral nutrition with fluid restriction 
Ccrcbral edema and increased intracranial pressure 
Severe burns 
Septic shock with multiple organ failure 
Hepatorenal syndrome 
Hepatic encephalopathy 
Cori-ection of acid-base dmturbancet 
Pulmonary edema 
catheter-related infections include the distinction 
between colonizationhfection and contamination by 
semiquantitation of catheter tip cultures, or defining 
catheter-related bactereniia as organisni(s) recovered 
from a catheter segment or tip with the same organ- 
ism(s) recovered froin blood cultures without clinical 
evidence of another source of infection [14-161. As 
patients on CH are likely to have more than one 
catheter, confirming a diagnosis of catheter-related 
bacteremia and determining its source is more difficult 
than in other patient groups. Diagnostic options 
include semiquantitative blood cultures taken through 
the hemofiltration catheter. However, this is tinie- 
consuming and cumbersome to perform. Alternatively, 
removal of the catheter for culture of the tip may be 
performed, but this is usually a difficult decision in 
patients with limited vascular access [17,1X]. Further- 
more, patients on CH may already be receiving 
treatment with multiple antimicrobial agents, reducing 
the chance of successfully culturing the organism(s) 
responsible. 
In a series of 17 patients receiving continuous 
arteriovenous hemodiafiltration (CAVHD) for renal 
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Figure 1 Schematic representation of continuouz 
venovenous hernofiltration ( C W H ) .  
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failure (mean duration 15 days), 35% of the catheters 
removed for suspected infection were colonized, but 
catheter-related infection was confirmed in only one 
patient [6]. No mention of the criteria used to 
distinguish colonization from infection was made. 
Yet another dificulty that may obscure clinical 
diagnosis, although less common with modern systems, 
is the effect of hemofiltration on core temperature, 
which may mask a pyrexial response. The reduction 
in core temperature observed can be explained in 
part by the extracorporeal circulation required for 
hernofiltration and the removal of pyrogens in the 
filtrate [19]. 
THERAPEUTIC POTENTIAL OF HEMOFllTRATlON 
FOR SEPSIS 
Hemofiltration has been advocated as a useful adjunct 
in the treatment of the sepsis syndrome both with 
and without multiple organ failure [20]. Experimental 
studies in animals have shown increased survival times 
in Staphylococcus aureus induced septicemia in immature 
swine, and beneficial effects on pulmonary artery 
wedge pressure and systemic vascular resistance in 
swine injected with Eschevichia coli endotoxin [21-231. 
A beneficial effect on ventricular contractility in dogs 
with induced E. coli septicemia has been demonstrated 
[24]. However, no increase in survival was seen in 
induced E. coli septicemia in dogs without renal failure 
[25]. Hemofiltration with dialysis has been shown to 
remove cytokines such as TNF-a, IL-IP, IL-6 and It- 
8, important in the cytokine cascade leading to septic 
shock and multiple organ failure, from the circulation 
of septic patients with acute renal failure [19,26,27]. 
Extrapolating the results of animal studies to humans 
is, however, difficult. A prospective multicenter, con- 
trolled trial recruiting large numbers of patients with 
septic shock and multiple organ failure would be 
required to demonstrate a therapeutic effect [28]. As 
mortality in this group is already over 60%, distinguish- 
ing death directly attributable to sepsis from that 
occurring in association with sepsis would be difficult 
[29,30]. 
A recent report of the successful use of hemo- 
diafiltration in the management of severe meningo- 
coccal septicemia in four children has stimulated much 
interest in the UK [31]. Although more formal trials are 
awaited, it has been suggested that the removal of 
cytokines and the entrapment of polymorph neutro- 
phils in the filter may partly explain the beneficial 
effects [32]. Replacement of the extracorporeal circuit 
may be required due to rapid accumulation of insoluble 
deposits in the air trap and filter. Whatever the impact 
on sepsis, it seems likely that CH will remain the 
treatment of choice for renal support in the ICU 
patient with severe hemodynamic instability, particu- 
larly in the absence of local facilities for hemodialysis 
[33,34]. 
CLEARANCE OF ANTIMICROBIAL AGENTS 
The effect of hemofiltration on the clearance of drugs 
will influence the dose, dosage interval and require- 
ment for measurement of antimicrobial agents. The 
efficiency of antimicrobial removal or filtration is 
related to the sieving coefficient (SC), which is a 
mathematical expression of the ability of a solute to 
cross a membrane by convection. The SC is also 
dependent on the degree of protein binding. An SC of 
close to 1 (e.g. amikacin, imipenem, ciprofloxacin, 
vancomycin) implies the agent crosses the membrane 
easily, whereas when the SC approaches zero (e.g. 
amphotericin B, oxacillin), there will be little removal 
[35]. For small molecules that pass freely into the 
filtrate, the filtration rate may be considered equivalent 
to the glomerular filtration rate in patients with normal 
renal function. 
Several agents have been studied in a handful of 
patients, resulting in guidelines that often conflict [36]. 
Furthermore, clearance of antimicrobial agents will 
vary with the hernofiltration modality used, type and 
make of filter, filtration rate, volume of ultrafiltrate 
produced, underlying renal function and general con- 
dition of the patient. Any treatment with antimicrobials 
must allow for all of these variables. 
Antimicrobial dosing of severely immuno- 
suppressed patients requiring hemofiltration is 
especially difficult, as they often receive treatment with 
several antimicrobial agents and require adequate serum 
and tissue cidal levels to achieve a successful outcome. 
Vos and colleagues have assessed the drug clearance of 
seven antibiotics by continuous hemodiafiltration in 
anuric patients and found that the dosages required for 
some patients were higher than expected [37]. A recent 
review with recommendations for antimicrobial pre- 
scribing in patients on hemofiltration has emphasized 
the enhanced clearance compared to hemodialysis with 
the risk of underdosing resulting, e.g. with vancomycin 
[38]. These guidelines are primarily based on educated 
guesswork, rather than documented experience, and 
originate from recommendations in the USA which are 
issued annually [39]. 
As a general rule and until further information 
becomes available, serum monitoring of antimicrobials 
is recommended, wherever possible. Dosage adjust- 
ments should then be made accordingly. Unfortunately, 
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referral to a national reference center, which is 
necessary for some agents, will result in a delay before 
dose adjustment can occur. In order to avoid errors in 
dose calculations, it is important to emphasize that 
the clearance of antimicrobials by hemofiltration is not 
equivalent to that following hemodialysis [36]. 
Beta-lactam agents 
In spite of the widespread use of cephalosporins for 
patients receiving CH,  the data available on their use 
are limited and often conflicting. Cefuroxime was 
studied in three adult patients on CAVH and the 
authors suggested an initial dose of 1.5 g followed by 
750 mg every 24 h [40]. They also recommended 
serum drug monitoring if continued beyond 72 h. For 
patients undergoing CAVHD, 500 to 750 mg cefu- 
roxime 12-hourly and 500 mg ceftazidime 12-hourly 
have been suggested [41]. For cefotaxime, one study 
which measured both cefotaxime and its active 
metabolite desacetylcefotaxime in eight patients with 
renal failure on CAVH, a dose of 1 g every 24 h was 
recommended [42]. Andrassy suggested that dosage 
adjustments for cefotaxime should be based on renal 
function with no adjustments during C H  [43] . 
The clearance of imipenem/cilastatin was assessed 
in 10 patients undergoing treatment with CAVH, 
following which a recommendation was made to 
modifi dosage on the basis of renal dysfunction [44]. 
Other workers have concluded that a fixed-dose 
combination of 500 mg twice a day is preferred with 
no further dosage adjustment considered necessary - on 
the basis that elimination of inlipenem by CAVH is low 
compared to cilastatin (7% versus 30% of dose 
respectively) [45]. Information on the clearance of 
meropenem by hemofiltration is awaited. 
Aminoglycosides and glycopeptides 
Aminoglycosides are cleared in part by hemofiltration; 
regular serum monitoring, which is available in most 
centers, is required before the next dose is given 
[46,47]. Vancomycin is cleared better by hemofiltration 
than hemodialysis alone. Slugg and colleagues studied 
18 patients with acute renal failure receiving either 
intermittent hemodialysis or CAVH/CAVHD and 
found that the latter group required larger doses of 
vancomycin at  shorter intervals [48]. High clearance of 
vancomycin was also described in six patients requiring 
CAVH for renal failure [49]. In another study, clear- 
ance of vancomycin on CAVHD was found to be 
approximately double that on CAVH [SO]. Regular 
serum monitoring (e.g. daily) is therefore required for 
patients undergoing hemofiltration, to determine the 
optimal dose in the individual patient [Sl]. 
Other antibacterials 
Dosage guidelines for ciprofloxacin in patients 
undergoing hemofiltration are similar to those in 
patients with normal renal function. Recommen- 
dations in adults undergoing treatment with CAVH, 
and CAVHD/CVVHD are 400 to 800mg/day and 
200 mg 8- to 12-hourly, respectively [52,531. The 
increased clearance of ciprofloxacin is likely to be 
related not only to increased extracorporeal clearance 
but also to the altered pharmacokinetics of this drug in 
seriously ill patients [53]. 
The trimethoprim component of co-trimoxazole 
has a large volume of distribution, and is unlikely to be 
removed by hemofiltration, whereas sulfamethoxazole 
is, leading to a selective accumulation of trimethoprim 
[54]. Clear guidelines are not available but it may be 
appropriate to reduce the trimethoprim component 
alone or in combination with the sulfonamide, based 
on renal function. Measurement of serum concen- 
trations of sulfamethoxazole and trimethoprim should 
ideally be performed on all patients with severe renal 
impairment. 
Antifungal agents 
There is little or no information on the clearance of 
amphotericin B by hemofiltration 1551. Liposomal 
amphotericin B was not detected in ultrafiltrate in one 
report and subsequently suggestions were made to give 
a standard dose initially, with a reduction if treatment 
is continued beyond 2 weeks [56]. Standard or higher 
doses of fluconazole are recommended, as this agent is 
cleared more efficiently by hernofiltration than by 
normal renal function [57]. Flucytosine is also removed 
by CH, and, following measurement in one patient, 
regular serum monitoring was recommended to guide 
dosage [%I. 
Antiviral agents 
Limited guidelines for antiviral agents are available 
[59,60]. The clearance of acyclovir by CAVHD is 
similar to that of CAPD (5.5 mL/min) which is 
considerably lower than clearance by conventional 
hemodialysis (82 mL/min). The dose therefore does 
not need to be increased for patients receiving 
hemofiltration [59]. Suggestions for a starting dose of 
ganciclovir are available from the manufacturer and 
are based on calculating the creatinine clearance by 
hemofiltration and following data sheet guidelines [60]. 
A dosage of 5 mg/kg/48 h has also been recommended 
based on three patients undergoing CVVHD, with 
adjustments made according to monitoring of plasma 
drug levels [61]. Foscarnet is not recommended 
for patients with a serum creatinine greater than 
250 pmol/L, and should therefore be avoided [62]. 
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CONCLUSIONS 
The availability of hemofiltration represents a 
potentially life-saving development in the care of 
the critically ill patient. Anesthetists, intensive care 
physicians, microbiologists and other healthcare staff 
should ensure good practice in relation to the insertion 
and care of hemofiltration catheters and maintain a 
high index of suspicion for diagnosing infection. The 
beneficial effects of hemofiltration on cytokine 
clearance as a therapeutic modality of clinical iinpor- 
tance remain to be confirmed. Finally, careful consider- 
ation must be given to the dose and frequency of 
administration of antimicrobial agents and, wherever 
possible, serum antibiotic assays should be performed. 
More precise recommendations based upon clinical 
studies are needed to support and substantiate the 
current empirical recommendations. 
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